160 related articles for article (PubMed ID: 32560270)
1. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
5. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
6. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.
Polański R; Noon AP; Blaydes J; Phillips A; Rubbi CP; Parsons K; Vlatković N; Boyd MT
Cancer Lett; 2014 Oct; 353(2):211-9. PubMed ID: 25067787
[TBL] [Abstract][Full Text] [Related]
7. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
8. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
Duan L; Perez RE; Lai X; Chen L; Maki CG
J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
13. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
14. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
15. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
17. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
18. Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Lee SH; Lee WK; Kim N; Kang JH; Kim KH; Kim SG; Lee JS; Lee S; Lee J; Joo J; Kwon WS; Rha SY; Kim SY
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463244
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]